FEBRUARY 18, 2012

Browse Categories

ASCO 2009 - On the Necessity for Postchemotherapy Surgery for Residual Abdominal Masses in Metastatic Nonseminomatous Germ Cell Tumors (NSGCT) of Testis - Session Highlights

Tue, 02 June 2009
E-mail Print

ORLANDO, FL, USA (UroToday.com) - Sunitinib has demonstrated activity as a second-line agent for patients with advanced urothelial carcinoma (UC) when administered on a 4 week on, 2 week off schedule.




Your session will expire in 8 hours requiring you to log in each day to view content.
Share |